# Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors

> **NCT01218529** · PHASE2 · COMPLETED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 82 (actual)

## Conditions studied

- Brain Metastases
- Lung Tumors
- Breast Tumors

## Interventions

- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT01218529
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-08
- **Final completion:** 2014-12
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2014-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218529, "Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01218529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*